Sessions:
Japan
2026 年 2 月 26 日, 星期四 – 1:00 pm – 5:00 pm
6th Floor, Room 6A, TKP Shinagawa Conference Center
Korea
2026 年 3 月 4 日, 星期三 – 1:00 pm – 5:00 pm
37th Floor, Room Zeus, ASEM Tower
概述
These interactive, hands-on workshop trains participants to use Certara IQ™, an AI-enabled QSP modeling platform that accelerates drug development. You will learn to build, optimize, and scale QSP models using AI-guided workflows, cloud-based simulations, and model libraries. Through the QSP case studies, you will see how Certara IQ streamlines systems pharmacology and supports confident decision-making across discovery to clinical stages.
Please select your preferred workshop location (Japan or Korea) when submitting your online registration.
Key takeaways
- Explore the latest QSP case studies and learn practical strategies to adopt QSP modeling in discovery and development projects for improved decision-making and accelerated innovation.
- Build and scale QSP models efficiently using AI-driven workflows, reusable model components, and cloud-based computing within Certara IQ.
- Optimize and validate models through automated parameter estimation, sensitivity analysis, and reproducibility tools to ensure regulatory readiness.
- Integrate QSP modeling software, Certara IQ, into cross-functional drug development workflows to enhance collaboration, data transparency, and translation from preclinical to clinical outcomes.
点击报名
议程
- Opportunities and challenges
- Certara IQ Application
- IQ Design Graphical Model Builder
- Generative AI for Model Validation
- (Demo) IQ Design
- Impact of QSP based EFA
- Implementing EFA with IQ Explore
- (Demo) IQ Explore
- Impact of QSP based FIH
- Intro to the First In Human Workflow
- (Demo) IQ Analyze and IQ First In Human Workflow
VP, Head of QSP Software, Certara
Dr. Apgar is the VP, Head of QSP Software at Certara, and co-founder of Applied BioMath (acquired by Certara in Dec 2023). Prior to this, Josh was a Principal Scientist in the Systems Biology Group of the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals. 他的工作是利用基于物理学的模型：转化体外和体内数据、评估靶点可行性、了解药物作用机制并预测人体剂量。这项工作的最终目标是通过对药物药理学和疾病病理生理学的深入定量研究，减少药物开发后期的损耗。
Joshua 在麻省理工学院获得生物工程博士学位，在那里他从事系统生物学的实验设计工作，研究重点是识别可以用于估算未知参数并揭示信号转导网络复杂机制的可操作性实验。在此之前，Joshua 在 Avaki开发了一个可扩展性极强的软件平台，以支持生命科学和工程领域的高性能计算和企业信息集成。
点击报名
